Arlington Acquires Riverpoint Medical
Search
Share on twitter
Share on linkedin
Share on print
Share on email

Arlington Acquires Riverpoint Medical

Arlington Capital Partners has acquired Riverpoint Medical. The investment in Riverpoint marks the first transaction for Arlington’s $1.7 billion fifth fund, which closed earlier this week.

Riverpoint Medical is a developer, designer, and manufacturer of medical devices focused on bio-medical textile technologies. The company specializes in bio-absorbable and non-absorbable sutures for the surgical and animal health markets. Riverpoint is also a provider of cordless LED surgical headlights and brachytherapy products for the oncology market. Brachytherapy is a procedure that involves placing radioactive material inside a body for the treatment of cancer. The company, led by CEO Pat Ferguson, was founded in 2008 by the Ferguson family and is headquartered in Portland, OR (www.rpmed.com).

Riverpoint’s founders and senior management have all made substantial investments in the company in partnership with Arlington. “We chose to partner with Arlington because of its long track record of success investing in, and scaling, medical device manufacturers,” said Mr. Ferguson. “We are extremely pleased to work together with Arlington to take Riverpoint to the next level of growth as Arlington shares our vision for expanding Riverpoint’s capabilities to better serve our customers and employees. Arlington’s ability to provide significant strategic and capital support is differentiated and will further enable Riverpoint to expand our offerings to our clients, increase our manufacturing capacity, and most importantly, help enhance surgical outcomes.”

“Arlington is thrilled to partner with the Riverpoint team to continue building a leading manufacturer of advanced textile-based medical devices,” said Matt Altman, a managing partner at Arlington. “Riverpoint’s ability to develop innovative technologies coupled with its unique manufacturing processes provide a strong platform to accelerate growth in large addressable markets. Our investment in Riverpoint continues Arlington’s history of building differentiated, high-growth medical device manufacturers in partnership with company founders and existing senior management.”

Arlington invests in buyouts and recapitalizations of companies valued from $50 million to $500 million that are active in government services and technology; aerospace and defense; healthcare; and business services and software.

“We have been very impressed with the company’s ability to capitalize on the growth trends in the sports medicine and animal health markets. We believe that Arlington can provide the strategic support and investments necessary to accelerate this exciting platform,” said Gordon Auduong, a vice president of Arlington.

Arlington was founded in 1999 and has completed over 90 acquisitions since its inception. The firm is based in Chevy Chase, MD (www.arlingtoncap.com).

© 2019 Private Equity Professional | June 28, 2019

Share on twitter
Share on linkedin
Share on print
Share on email

To search in site, type your keyword and hit enter